Aquestive Therapeutics (AQST) Tax Provisions (2023 - 2024)
Aquestive Therapeutics (AQST) posted quarterly Tax Provisions of -$14000.0 for Q4 2024, down 113.86% year-over-year from $101000.0 in Q1 2024, and down 113.86% quarter-over-quarter from $101000.0 in Q4 2023.
Aquestive Therapeutics (AQST) Tax Provisions (2023 - 2024) Analysis & Trends
Aquestive Therapeutics' Tax Provisions history runs 2 years deep, the most recent figure standing at -$14000.0 for Q4 2024.
- In Q4 2024, Tax Provisions fell 113.86% year-over-year to -$14000.0; the TTM figure through Mar 2025 stood at -$14000.0 (down 105.71% YoY), while the FY2024 annual figure was -$14000.0, down 105.71% from the prior year.
- Tax Provisions for Q4 2024 stood at -$14000.0, down from $101000.0 in the prior quarter.
- The five-year high for Tax Provisions was $284000.0 in Q2 2023, with the low at -$140000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 121.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -310.32 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 39.70 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 54.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 17.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 2.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Aquestive Therapeutics | 560.60 Mn | 560.60 Mn | 9.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -14,000.00 |
| Dec 31, 2023 | 101,000.00 |
| Sep 30, 2023 | -140,000.00 |
| Jun 30, 2023 | 284,000.00 |